Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ABBV – AbbVie Inc.

AbbVie Inc.
ABBV
$190.08
Name : AbbVie Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $335,760,850,944.00
EPSttm : 2.34
finviz dynamic chart for ABBV
AbbVie Inc.
$190.08
1.41%
$2.64

Float Short %

1.13

Margin Of Safety %

5

Put/Call OI Ratio

0.74

EPS Next Q Diff

0.75

EPS Last/This Y

9.84

EPS This/Next Y

1.71

Price

187.47

Target Price

213.83

Analyst Recom

1.83

Performance Q

-11.05

Relative Volume

0.56

Beta

0.49

Ticker: ABBV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07ABBV187.620.800.24393474
2025-05-08ABBV185.590.821.56392801
2025-05-09ABBV184.520.835.41396740
2025-05-12ABBV190.70.942.25413077
2025-05-13ABBV187.930.840.54409465
2025-05-14ABBV176.90.841.14414813
2025-05-15ABBV181.590.833.99419352
2025-05-16ABBV183.980.820.52424298
2025-05-19ABBV185.760.760.40328983
2025-05-20ABBV184.890.740.90341379
2025-05-21ABBV181.720.740.61346317
2025-05-22ABBV182.450.730.67348305
2025-05-23ABBV183.260.730.78351862
2025-05-27ABBV185.460.730.52340142
2025-05-28ABBV183.030.732.15344025
2025-05-29ABBV185.560.762.09353042
2025-05-30ABBV186.370.761.00358941
2025-06-02ABBV186.960.750.55347307
2025-06-03ABBV187.280.730.44353416
2025-06-04ABBV187.320.740.37358736
2025-06-05ABBV187.480.740.82360692
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07ABBV188.0919.821505.312.23
2025-05-08ABBV185.6019.821075.312.23
2025-05-09ABBV184.5519.821257.212.25
2025-05-12ABBV190.0719.822083.412.25
2025-05-13ABBV187.9819.821183.712.25
2025-05-14ABBV177.4819.820133.812.25
2025-05-15ABBV181.8420.122014.612.25
2025-05-16ABBV183.9620.121732.512.25
2025-05-19ABBV185.7120.121654.812.25
2025-05-20ABBV184.9020.121338.612.25
2025-05-21ABBV181.7720.121053.512.25
2025-05-22ABBV182.4120.121519.012.25
2025-05-23ABBV183.2620.121533.212.25
2025-05-27ABBV185.7220.121753.212.25
2025-05-28ABBV183.0320.121103.312.25
2025-05-29ABBV185.5020.121747.012.25
2025-05-30ABBV186.1120.121502.412.25
2025-06-02ABBV186.9120.121541.212.24
2025-06-03ABBV187.2520.121473.412.24
2025-06-04ABBV187.3220.121449.712.24
2025-06-05ABBV187.4720.121457.212.24
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07ABBV-12.610.390.95
2025-05-08ABBV-12.610.390.95
2025-05-09ABBV-12.610.390.95
2025-05-12ABBV-12.610.211.12
2025-05-13ABBV-12.610.211.12
2025-05-14ABBV-12.620.211.12
2025-05-15ABBV-12.620.211.12
2025-05-16ABBV-12.620.211.12
2025-05-19ABBV-12.621.441.12
2025-05-20ABBV-15.011.441.12
2025-05-21ABBV-15.011.441.12
2025-05-22ABBV-15.011.441.12
2025-05-23ABBV-15.011.441.12
2025-05-27ABBV-15.010.311.12
2025-05-28ABBV-15.010.311.13
2025-05-29ABBV-15.010.311.13
2025-05-30ABBV-15.010.311.13
2025-06-02ABBV-15.010.881.13
2025-06-03ABBV-15.010.881.13
2025-06-04ABBV-15.010.881.13
2025-06-05ABBV-15.010.881.13
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

2.46

Avg. EPS Est. Current Quarter

3.18

Avg. EPS Est. Next Quarter

3.21

Insider Transactions

-15.01

Institutional Transactions

0.88

Beta

0.49

Average Sales Estimate Current Quarter

14931

Average Sales Estimate Next Quarter

15341

Fair Value

197.7

Quality Score

75

Growth Score

83

Sentiment Score

75

Actual DrawDown %

14.3

Max Drawdown 5-Year %

-21.9

Target Price

213.83

P/E

79.94

Forward P/E

13.4

PEG

5.25

P/S

5.77

P/B

233.19

P/Free Cash Flow

21.52

EPS

2.35

Average EPS Est. Cur. Y​

12.24

EPS Next Y. (Est.)

13.95

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

7.24

Relative Volume

0.56

Return on Equity vs Sector %

268.6

Return on Equity vs Industry %

260.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

21457.2
AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 55000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
stock quote shares ABBV – AbbVie Inc. Stock Price stock today
news today ABBV – AbbVie Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABBV – AbbVie Inc. yahoo finance google finance
stock history ABBV – AbbVie Inc. invest stock market
stock prices ABBV premarket after hours
ticker ABBV fair value insiders trading